Conmed/$CNMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Conmed
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Geographically operates in USA, Europe, Middle East & Africa, Asia Pacific and North America. Majority is revenue is from USA.
Ticker
$CNMD
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,900
ISIN
US2074101013
Website
Conmed Metrics
BasicAdvanced
$1.7B
14.06
$3.81
1.29
$0.80
1.49%
Price and volume
Market cap
$1.7B
Beta
1.29
52-week high
$75.43
52-week low
$46.00
Average daily volume
383K
Dividend rate
$0.80
Financial strength
Current ratio
2.257
Quick ratio
0.906
Long term debt to equity
91.184
Total debt to equity
91.257
Dividend payout ratio (TTM)
20.78%
Interest coverage (TTM)
4.43%
Profitability
EBITDA (TTM)
223.195
Gross margin (TTM)
56.28%
Net profit margin (TTM)
9.02%
Operating margin (TTM)
11.59%
Effective tax rate (TTM)
18.26%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
4.14%
Return on equity (TTM)
12.96%
Valuation
Price to earnings (TTM)
14.056
Price to revenue (TTM)
1.258
Price to book
1.72
Price to tangible book (TTM)
-3.58
Price to free cash flow (TTM)
10.058
Free cash flow yield (TTM)
9.94%
Free cash flow per share (TTM)
532.63%
Dividend yield (TTM)
1.49%
Forward dividend yield
1.49%
Growth
Revenue change (TTM)
4.32%
Earnings per share change (TTM)
46.38%
3-year revenue growth (CAGR)
8.85%
10-year revenue growth (CAGR)
5.98%
3-year earnings per share growth (CAGR)
22.08%
10-year earnings per share growth (CAGR)
13.44%
What the Analysts think about Conmed
Analyst ratings (Buy, Hold, Sell) for Conmed stock.
Bulls say / Bears say
Conmed reported Q4 2024 sales of $345.9 million, a 5.8% year-over-year increase, driven by strong performance in General Surgery and the AirSeal platform. (seekingalpha.com)
The company anticipates 2025 revenue between $1.344 billion and $1.372 billion, representing 4-6% constant currency growth, indicating confidence in sustained growth. (seekingalpha.com)
Conmed has improved its supply chain outlook, which could enhance operational efficiency and product availability. (seekingalpha.com)
J.P. Morgan downgraded Conmed to Neutral from Overweight after Q4 2024 results, citing a 2025 outlook that fell short of consensus expectations. (seekingalpha.com)
Barclays PLC decreased its holdings in Conmed by 88.1% during the fourth quarter, potentially indicating reduced confidence from institutional investors. (marketbeat.com)
Wells Fargo maintained a Hold rating on Conmed, suggesting a cautious stance on the company's near-term performance. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Conmed Financial Performance
Revenues and expenses
Conmed Earnings Performance
Company profitability
Conmed News
AllArticlesVideos
Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc.
Business Wire·4 days ago
CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025
Business Wire·1 week ago
CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Conmed stock?
Conmed (CNMD) has a market cap of $1.7B as of July 12, 2025.
What is the P/E ratio for Conmed stock?
The price to earnings (P/E) ratio for Conmed (CNMD) stock is 14.06 as of July 12, 2025.
Does Conmed stock pay dividends?
Yes, the Conmed (CNMD) stock pays dividends to shareholders. As of July 12, 2025, the dividend rate is $0.8 and the yield is 1.49%. Conmed has a payout ratio of 20.78% on a trailing twelve-month basis.
When is the next Conmed dividend payment date?
The next Conmed (CNMD) dividend payment date is unconfirmed.
What is the beta indicator for Conmed?
Conmed (CNMD) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.